Tiziana Life Sciences Highlighted in Forbes Article
March 17, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Global Naloxone Market to surpass US$ 2,460.2 Million by 2030, Says Coherent Market Insights (CMI)
July 20, 2022 09:10 ET
|
CMI
Seattle, July 20, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights’ analysis, the global naloxone market is estimated to be valued at US$ 1,118.3 Million in 2022 and is expected to...
Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries
July 18, 2022 08:00 ET
|
Medigus Ltd
Polyrizon will be entitled for up to $3.35 million in addition to future royalties Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged...
Ebvia Announces Positive Results Published in Nature for TMPRSS2 Inhibitor for the Prevention and Treatment of COVID-19
March 29, 2022 09:00 ET
|
Ebvia
SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Ebvia, a biotechnology developing simple-to-use therapeutics for the treatment and prevention of COVID-19, today announces the publication entitled...
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
February 08, 2022 07:30 ET
|
Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
Intranasal Drug Delivery Devices Market Size to Hit Around US$ 2.98 Billion by 2030
May 26, 2021 10:00 ET
|
Precedence Research
OTTAWA, May 26, 2021 (GLOBE NEWSWIRE) -- Precedence Research says, the global intranasal drug delivery devices market was valued at USD 1.17 billion in 2020. Drug delivery primarily refers to a...
CFN Media Interviews David Sutton of NanoSphere Health Sciences Inc.
May 22, 2018 08:40 ET
|
CFN Media
SEATTLE, May 22, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication...
Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated
August 14, 2017 08:30 ET
|
LinkedIn
PHILADELPHIA, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has commenced full data analysis of an intranasal human safety study of Ampligen® plus FluMist®...
FDA Authorizes New Hemispherx Biopharma Clinical Trial of Intranasal Ampligen(R) With Seasonal Influenza Vaccine
July 20, 2011 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 20, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced it has received U.S. Food Drug Administration (FDA)...